Mangalam Drugs & Organics Limited (BOM:532637)
India · Delayed Price · Currency is INR 73.74
-5.46 (-6.89%)
At close: Aug 28, 2025
Mangalam Drugs & Organics Revenue
Mangalam Drugs & Organics had revenue of 572.09M INR in the quarter ending June 30, 2025, a decrease of -25.21%. This brings the company's revenue in the last twelve months to 2.98B, down -16.41% year-over-year. In the fiscal year ending March 31, 2025, Mangalam Drugs & Organics had annual revenue of 3.18B, down -13.55%.
Revenue (ttm)
2.98B
Revenue Growth
-16.41%
P/S Ratio
0.39
Revenue / Employee
6.90M
Employees
432
Market Cap
1.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.18B | -497.78M | -13.55% |
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | 3.80B | 976.24M | 34.57% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Hindustan Unilever | 639.28B |
| Infosys | 1,672.76B |